1. Pharmacoeconomic Evaluation in the Real World

   • Dennis A. Revicki
   • Lori Frank

   Leading Article 11 October 2012 Pages: 423 - 434

2. Prescribing at the Interface Between Primary and Secondary Care in the UK

   • Martin Duerden
   • Tom Walley

   Leading Article 11 October 2012 Pages: 435 - 443

3. Counting the Costs of Drug-Related Adverse Events

   • T. Jeffrey White
   • Annet Arakelian
   • Jay P. Rho

   Review Article 11 October 2012 Pages: 445 - 458

4. The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals

   • Dr Judith L. Glennie
   • George W. Torrance
   • Marc Rivière

   Review Article 11 October 2012 Pages: 459 - 468

5. Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia

   • Susan H. Hamilton
   • Dennis A. Revicki
   • Gary Tollefson

   Original Research Article 11 October 2012 Pages: 469 - 480

6. Reconciling Decision Models With the Real World

   • Ya-Chen Tina Shih
   • Teresa L. Kauf

   Original Research Article 11 October 2012 Pages: 481 - 493

7. Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy

   • Robert I. Griffiths
   • Erin M. Sullivan
   • Howard H. Goldman

   Original Research Article 11 October 2012 Pages: 495 - 505

8. Direct Costs of Hip Fractures in Patients Over 60 Years of Age in Belgium

   • Jean-Yves Reginster
   • Pierre Gillet
   • Christiane Gosset

   Original Research Article 11 October 2012 Pages: 507 - 514